Journal
CURRENT CANCER DRUG TARGETS
Volume 8, Issue 8, Pages 733-740Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800908786733504
Keywords
PIK3CA; mutation; oncogene; PI3 kinase; AKT; mTOR
Categories
Funding
- The Flight Attendant's Medical Research Institute (FAMRI)
- NIH/NCI [CA109274]
- Summer Running Fund
- Cure Foundation
- Mary Kay Ash Charitable Foundation
- Avon Foundation
- Department of Defense Breast Cancer Research Program Predoctoral Fellowship Award [W81XWH-06-1-0325]
- NIH Institutional Training [T32 CA09071]
- ASCO Cancer Foundation Young Investigator Award
Ask authors/readers for more resources
The development of targeted therapies with true specificity for cancer relies upon exploiting differences between cancerous and normal cells. Genetic and genomic alterations including somatic mutations, translocations, and amplifications have served as recent examples of how such differences can be exploited as effective drug targets. Small molecule inhibitors and monoclonal antibodies directed against the protein products of these genetic anomalies have led to cancer therapies with high specificity and relatively low toxicity. Recently, our group and others have demonstrated that somatic mutations in the PIK3CA gene occur at high frequency in breast and other cancers. Moreover, the majority of mutations occur at three hotspots, making these ideal targets for therapeutic development. Here we review the literature on PIK3CA mutations in cancer, as well as existing data on PIK3CA inhibitors and inhibitors of downstream effectors for potential use as targeted cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available